158 related articles for article (PubMed ID: 38457360)
1. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
[TBL] [Abstract][Full Text] [Related]
2. T cells, particularly activated CD4
Wang Z; Chimenti MS; Strouse C; Weiner GJ
Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity.
Wang Z; Yin C; Lum LG; Simons A; Weiner GJ
J Hematol Oncol; 2021 Dec; 14(1):204. PubMed ID: 34886888
[TBL] [Abstract][Full Text] [Related]
4. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
Front Immunol; 2019; 10():1943. PubMed ID: 31475004
[TBL] [Abstract][Full Text] [Related]
5. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
6. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
7. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
[TBL] [Abstract][Full Text] [Related]
9. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
11. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
12. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
[TBL] [Abstract][Full Text] [Related]
13. Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells
Niu C; Chen Y; Li M; Zhu S; Zhou L; Xu D; Li Z; Xu J; Li W; Wang Y; Cui J
Front Immunol; 2021; 12():658562. PubMed ID: 34113342
[TBL] [Abstract][Full Text] [Related]
14. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
15. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Wang SY; Racila E; Taylor RP; Weiner GJ
Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
[TBL] [Abstract][Full Text] [Related]
16. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
17. Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.
Hassenrück F; Knödgen E; Göckeritz E; Midda SH; Vondey V; Neumann L; Herter S; Klein C; Hallek M; Krause G
Biomed Res Int; 2018; 2018():1023490. PubMed ID: 29750146
[TBL] [Abstract][Full Text] [Related]
18. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
19. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
20. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
Binyamin L; Alpaugh RK; Hughes TL; Lutz CT; Campbell KS; Weiner LM
J Immunol; 2008 May; 180(9):6392-401. PubMed ID: 18424763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]